<DOC>
	<DOCNO>NCT01695005</DOCNO>
	<brief_summary>The purpose study find recommended dose level LY3039478 safely take participant advanced cancer cancer spread part body , include limited lymphoma . The study also explore change various marker blood cell tissue . Finally , study help document tumor activity drug may .</brief_summary>
	<brief_title>A Study LY3039478 Participants With Advanced Cancer</brief_title>
	<detailed_description>In Part A study , participant advanced/metastatic cancer ( include lymphoma ) receive increase dos LY3039478 define dose level Part B , C , D E. In Part B , C , D E LY3039478 explore predefined fix dose level . Participants Part B D must define alteration certain molecular pathway . Enrollment participant Part B , C , D E start Part A complete . In Part F participant receive increase dos LY3039478 combination prednisone define maximum tolerate dose level .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>For part : The participant must , judgment investigator , appropriate candidate experimental therapy available standard therapy fail provide clinical benefit advance metastatic cancer . For Dose Escalation ( Part A ) : The participant must histological cytological evidence cancer , either solid tumor lymphoma , advance metastatic . For Part B : All participant must histological evidence advanced metastatic cancer prescreened alteration define pathway . For Part C : All participant must histological evidence advanced metastatic specific subtypes soft tissue sarcoma . For Part D : All participant must histological evidence advanced metastatic cancer prescreened alteration define pathway . Cohort 1 : Participants must triple negative breast cancer . Cohort 2 : Participants must hepatocellular carcinoma ( HCC ) . These participant ChildPugh stage A. Cohort 3 : Participants must cholangiocarcinoma . Cohort 4 : Participants must chronic lymphocytic leukemia . Cohort 5 : Participants must mature T cell , B cell , natural killer ( NK ) cell neoplasm . For Part E : Participants must adenoid cystic carcinoma ( ACC ) . For Part F dose confirmation : Participants must leiomyosarcoma prescreened alteration define pathway . As defined Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) , Revised Response Criteria Malignant Lymphoma Response Assessment Neuro Oncology ( RANO ) criterion glioblastoma : For Dose Escalation ( Part A ) : Have measurable nonmeasurable disease . For Parts B , C , D , E F : Have measurable disease reliable biomarker measure . For Parts B , C , D , E F : Have available tumor tissue . Have adequate organ function . Have performance status less equal 1 Eastern Cooperative Oncology Group ( ECOG ) scale life expectancy 12 week . Have symptomatic non stable central nervous system ( CNS ) malignancy . Females pregnant lactating . Have active bacterial , fungal , and/or know viral infection . Have malabsorptive syndrome , enteropathy , gastroenteritis ( acute chronic ) , diarrhea ( acute chronic ) . Participants HCC : Have know HCC fibrolamellar mixed histology . Have presence clinically relevant ascites . Have liver transplant . Have active uncontrolled clinically serious hepatitis B virus hepatitis C virus infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>